Danish researchers analyzed data from over 77,000 adults taking anti-obesity medications without diabetes. They discovered that 52 percent stopped within one year. Eighteen percent quit within three months, 31 percent within six months, and 42 percent after nine months. Patients under 30 quit 48 percent more than adults aged 45 to 59. People living in low-income areas stopped 14 percent more often than those in wealthier neighborhoods. Men showed higher dropout rates than women.
GLP-1 Medications Require Long-Term Commitment
Ozempic and Wegovy, part of the GLP-1 receptor agonist class, mimic a hormone that reduces appetite. Researchers warned that patients often regain weight after discontinuing treatment. Professor Reimar W. Thomsen of Aarhus University stressed, “These medications lose all appetite control benefits once patients stop taking them.” He added, “They are not temporary fixes; long-term adherence is essential for effectiveness.”
Side Effects and Previous Medications Influence Dropouts
Researchers found that patients who previously used psychiatric or gastrointestinal drugs were more likely to quit, likely due to side effects like nausea or vomiting. Chronic health conditions also increased dropout risk.
Costs Pose a Barrier to Continuation
In Denmark, a month’s supply of Ozempic costs up to €313 for non-diabetic patients, compared to €120 in Germany. Researchers suggested high prices may limit accessibility for people in lower-income areas.
Implications for Public Health and Support Strategies
Thomsen emphasized that proper support can help patients maintain treatment and reduce long-term health risks. “These drugs lower risks of heart disease, cancer, and addiction,” he said. He added, “With over half of European adults overweight or obese, targeted interventions to encourage adherence can improve health outcomes and quality of life.”
Upcoming Presentation and Research Dissemination
The findings will be presented at the European Association for the Study of Diabetes annual meeting in Vienna this week. Thomsen encouraged policymakers and healthcare providers to develop strategies that improve patient support and ensure long-term benefits from these medications.
